

Bacopa monnieri (Brahmi): Bridging Traditional Wisdom and Modern Neuropharmacology for Memory Enhancement and Neuroprotection

Deep Jyoti Shah^{1*}, Ankita Singh², Mahesh Kumar Yadav², Indrajeet Kumar Mahto³, Arnab Roy³

^{1*} Corresponding Author, Assistant Professor, Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India.

² Associate Professor, Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India.

³ Assistant Professor, Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India.

Abstract

The *B. monnieri* L. Wettst (Brahmi) has been used traditionally in Ayurvedic medicine for thousands of years to enhance cognitive function and has also been used to treat various neurological conditions. In this literature review, we will focus on the botanical, ethnopharmacological, phytochemical and pharmacological aspects of *B. monnieri* with an emphasis on the herb's neuropharmacological effects. The herb's active ingredients, such as bacosides, have shown to improve memory functions and protect neurons from damage by enhancing synaptic plasticity, regulating the release of neurotransmitters and protecting against oxidative stress. In addition to summarizing the current state of knowledge regarding *B. monnieri*, this paper will evaluate the herb's toxicology and identify areas that need additional study.

Keywords: *Bacopa monnieri*, Brahmi, bacosides, memory enhancement, neuroprotection, Ayurveda, cognitive function

1. Introduction

Cognitive disorders and neurodegenerative diseases remain on the increasing list of global burdens with aging population, and there is a pressing need to develop safe and effective treatment interventions. The existing medication available in the market is still inadequate in terms of its effects and commonly has significant adverse effects, which has revived the idea of using traditional medicines based on botanical remedies for cognitive improvement. *Bacopa monnieri* (L.) Wettst., a plant of the family Plantaginaceae, is one of the most significant nootropic herbs of the Ayurvedic pharmacopeia. Known as “Brahmi” in Sanskrit, derived from the name of Hindu god of creation, “Brahma”, and the traditional beliefs of the herb are

associated with increased consciousness and intelligence. Ayurvedic practitioners advised the use of *B. monnieri* for improving memory, learning capacity, and mental sharpness and to cure epilepsy, insomnia, and anxiety for over 3,000 years [1]. Numerous bioactive chemicals have been found in *B. monnieri* by modern phytochemical investigations; the main active constituents are believed to be bacosides, which are dammarane-type triterpenoid saponins. These compounds show outstanding neuroprotective and cognitive-enhancing effects in both preclinical and clinical studies, which ensures the traditional use of many centuries and provides evidence of sophisticated molecular pathways.

2. Botanical Description and Taxonomy

2.1 Taxonomic Classification

Taxonomic Rank	Classification
Kingdom	Plantae
Division	Magnoliophyta
Class	Magnoliopsida
Order	Lamiales
Family	Plantaginaceae (formerly Scrophulariaceae)
Genus	Bacopa
Species	monnieri

Table 1: Taxonomic classification of *Bacopa monnieri* [2]



Fig. 1: *Bacopa monnieri* herb

Source:https://www.mindlabpro.com/blogs/nootropics/bacopa-monneri?srsltid=AfmBOooee7n_MZg4N5s2wW5t3H1uWicPQ6lya5rAKJD1ulctqqE8C05B

2.2 Morphological Characteristics

Plant Part	Characteristics
Growth Habit	Prostrate or ascending; perennial, creeping herb
Stems	Soft, succulent, glabrous; 10-30 cm long; root readily at nodes
Leaves	Oppositely arranged or whorled; sessile/subsessile; oblong or spatulate; 8-20 mm long × 4-9 mm wide; entire margins; thick, succulent texture
Flowers	Solitary, axillary; 5 unequal sepals; white, pale blue, or purple corolla
Fruits	Small, ovoid capsules with numerous minute seeds

Table 2: Morphological characteristics of *Bacopa monnieri* [3]

2.3 Distribution and Habitat

Bacopa monnieri exhibits a pantropical distribution and is naturally found in wetlands, marshes, and shallow water bodies in the tropical and subtropical areas. The species are native to India and distributed throughout the Southeast Asian region, Australia, Europe, Africa, and the Americas. The plant is semi-aquatic, and it likes muddy media and standing shallow water [4].

3. Traditional and Ethnomedicinal Uses

3.1 Ayurvedic Perspective

Aspect	Description
Ayurvedic Classification	Medhya Rasayana (cognitive enhancer and rejuvenator)
Dosha Effects	Pacifies Vata and Kapha; may aggravate Pitta in excess
Traditional Preparations	Fresh juice (swarasa), decoctions (kwatha), clarified butter preparations (ghrita)
Dosage	3-6 g dried herb powder or 10-20 ml fresh juice daily
Administration	With honey, ghee, or milk for enhanced bioavailability
Primary Indications	Cognitive enhancement, memory improvement, learning capacity
Other Indications	Epilepsy, insomnia, anxiety, mental disorders
Pediatric Use	Improving learning capacity and academic performance

Table 3: Traditional Ayurvedic uses and preparations of *Bacopa monnieri* [5]

3.2 Global Ethnomedicinal Applications

In other cultures, the medicinal properties of *B. monnieri* have been independently discovered in several other countries outside of India. The herb is used in Traditional Chinese Medicine in the treatment of cardiovascular disorders. In the traditions of folk medicine practiced in tropical Asia, it is used to treat respiratory diseases, especially asthma and bronchitis, skin diseases, and digestive diseases. The uniformity of application in the varied cultural contexts for cognitive enhancement offers strong ethnopharmacological support that drives modern scientific examination [6].

4. Phytochemical Profile

4.1 Major Bioactive Constituents

Phytochemical Class	Major Compounds	Characteristics
Bacosides (Triterpenoid Saponins)	Bacoside A, B, C	Primary active principles; 5-12% of dried plant; marker compounds for standardization
Other Saponins & Glycosides	Bacopasides I-XII; Bacopasaponins A-G; Monnierin	Synergistic pharmacological contributions
Alkaloids	Brahmine; Herpestine; Nicotine	Present in minor quantities; modulatory roles
Flavonoids & Polyphenols	Luteolin; Apigenin; Quercetin derivatives	Antioxidant properties; neuroprotection
Other Constituents	Betulic acid; Stigmasterol; β -sitosterol; Essential oils	Additional therapeutic effects

Table 4: Major phytochemical constituents of *Bacopa monnieri* [7]

4.2 Factors Affecting Composition [8]




Fig. 2: Factors affecting bacoside concentration in *Bacopa monnieri*.

Because of these variations, commercial extracts must be carefully standardized in order to assure constant therapeutic efficacy.

5. Pharmacological Activities

5.1 Cognitive Enhancement and Nootropic Effects

Preclinical research has shown that *B. monnieri* extracts boost learning and memory in a wide range of paradigms, such as the Morris water maze, passive avoidance tests, and the radial arm maze tests. The effects include enhancement of spatial learning, lowering of latency in memory tasks, and improvement in retention that comes out to be dose-dependent and progresses with further administration.

Systematic reviews on healthy human subjects show that *B. monnieri* supplementation enhances free recall memory, particularly after 8-12 weeks of administration. There is an increase in attention, cognitive processing, and working memory. The late onset is consistent with the processes of structural neuroplasticity rather than the direct stimulation of the neurotransmitter [9,10].

5.2 Neuroprotective Effects

B. monnieri has proven to have great neuroprotective activity with respect to neurodegenerative diseases. Research on the models of Alzheimer's disease has indicated that the herb lowers the amyloid-beta deposits, prevents the amyloid toxicity, and adjusts the tau protein phosphorylation. It helps shield the dopaminergic neurons in models of Parkinson's disease against degeneration as a result of toxins [11].

5.3 Antioxidant Activity

B. monnieri improves the natural antioxidant systems by increasing superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). The herb increases low levels of glutathione and reduces lipid peroxidation markers like malondialdehyde (MDA) in brain tissue, thereby protecting neuronal membranes from oxidative damage [12].

5.4 Anxiolytic and Anti-inflammatory Properties

Dosage-dependent anxiolytic effects such as those of benzodiazepines are found in animal studies but without sedation and cognitive impairment. Human clinical trials indicate anxiety reduction and stress response growth. *B. Monnieri*'s anti-inflammatory effects include reducing the levels of pro-inflammatory cytokines (TNF- α , IL-1 β , and IL-6) and resistance to COX and LOX enzyme activity [13,14].

6. Mechanisms of Action in Neuroprotection and Memory Enhancement

Mechanism	Effects
Neurotransmitter Modulation	Inhibits acetylcholinesterase; increases acetylcholine availability; modulates serotonin, dopamine, and GABA systems
Synaptic Plasticity	Increases dendritic branching and synaptic density; facilitates long-term potentiation (LTP); promotes neurogenesis
Protein Synthesis & Gene Expression	Upregulates synapsin, syntaxin, postsynaptic density proteins; increases BDNF levels; modulates stress response genes
Antioxidant Defense	Enhances SOD, CAT, GPx activities; reduces oxidative stress markers; scavenges free radicals
Cerebrovascular Effects	Enhances cerebral blood flow; improves endothelial function; antiplatelet activity
Anti-inflammatory Action	Modulates microglial activation; reduces inflammatory cytokines; inhibits inflammatory enzymes

Table 5: Mechanisms of action of *Bacopa monnieri* in neuroprotection [15]

These Herbs increases acetylcholine availability through acetylcholinesterase inhibition, increased choline acetyltransferase activity, and increased receptor expression. Research has shown that the dendritic length and branch points in the hippocampal neuron have increased, which is related to improved memory performance. *B. monnieri* upregulates brain-derived neurotrophic factor (BDNF), which is important for the neuronal survival and synaptic plasticity.




Fig. 3: Neuroprotective effects of bacoside from *Bacopa monnieri*.

Sources: <https://journals.sagepub.com/doi/10.1177/1177392819866412>

7. Modern Neuropharmacological Studies

7.1 Preclinical Evidence

Neuropharmacological actions of *B. monnieri* have been well supported with strong evidence via extensive preclinical research using cell culture, tissue preparations, and animal models. Cognitive improvement in a wide range of memory paradigms and effectiveness has been shown in animal models of Alzheimer's disease, Parkinson's disease, epilepsy, and traumatic brain injury. Pharmacokinetic experiments indicate that bacosides are able to cross the blood-brain barrier and attain pharmacologically relevant concentrations in brain tissues.

7.2 Clinical Trials

B. monnieri cognitive effects in humans have been studied in a variety of randomized, double-blind, placebo-controlled trials. According to meta-analyses, positive effects on memory and especially free recall and delayed recall performance are possible. Cognitive flexibility, information processing, and attention have been reported to be improved.

Research in children with learning impairments and ADHD has indicated its usefulness in terms of attention, decreasing hyperactivity, and enhancing the ability to control impulse. In the elderly, trials have shown that the deterioration in cognition can be slowed by the supplementation. The majority of the positive studies used standardized extracts of 20-55% bacosides in doses of 300-450 mg/day over 8-12 weeks [16].

7.3 Limitations

The existing clinical data is limited in such aspects as small sample size, 8-12 weeks in length of a study, inconsistency in the standardization of extracts, and insufficiency of research in clinical groups of patients with diagnosed neurodegenerative diseases. The majority of studies involve healthy individuals or individuals with mild cognitive impairment and cannot generalize to how it affects therapeutic effects in cases of severe neurodegeneration.

8. Synergistic and Formulation Studies

In Ayurvedic traditional medicine, *B. monnieri* is found in complex polyherbal preparations, like Brahmi Ghrita and Saraswatarishta, with *Centella asiatica*, *Withania somnifera*, and other herbs. The recent studies of polyherbal preparations indicate that combinations can be more effective than single herbs [17].

Modern studies cover the interactions of synergy with *Ginkgo biloba*, omega-3 fatty acids, and phosphatidylserine. Nanoparticle preparations, liposomal preparations, and phospholipid complexation have been studied by formulation science, which exhibits better pharmacokinetics and possibly greater clinical efficacy.

9. Toxicology and Safety Profile

9.1 Preclinical Safety

A substantial amount of toxicological testing makes *B. monnieri* remarkably safe and gives it a broad therapeutic window. Acute, subacute, and chronic toxicity tests indicate the absence of any major organ toxicity, hematological abnormalities, or histopathology at therapeutic dosages. Reproductive and developmental literature suggests that at therapeutic doses it has no teratogenic effects. Genotoxicity tests are consistently negative in nature, which means that it has no mutagenic or carcinogenic effect.

9.2 Clinical Safety

Safety Aspect		Findings
Common Adverse Effects		Mild gastrointestinal symptoms (nausea, cramping, increased bowel movements)
Less Common Effects		Dry mouth, fatigue, mild headache (rare, infrequent)
Serious Adverse Effects		None reported in clinical trials
Drug Interactions		Potential interactions with cholinergic medications, thyroid hormones, sedatives, anticoagulants
Contraindications		Thyroid disorders, slow heart rate, pregnancy/lactation (insufficient safety data)

Table 6: Clinical safety profile of *Bacopa monnieri* [18]

In clinical trials shown excellent tolerability at the recommended doses. A majority of the adverse effects are mild and disappear as one continues taking them. Persons who have thyroid disorders, heart disorders, or use prescription drugs should seek medical advice before using it.

10. Research Gaps and Future Perspectives

10.1 Critical Knowledge Gaps

There are considerable gaps in research on the relative contribution of each bacoside compared to the full phytochemical profile, long-term efficacy, safety after 12 weeks, optimum dose-response relationships, and full molecular mechanism. There should be an increase in clinical studies on the particular patient group with confirmed Alzheimer's disease, vascular dementia, and Parkinson's disease.

10.2 Future Research Directions

Research Area	Priority Directions
Clinical Trials	Large-scale trials with standardized extracts, validated outcomes, adequate follow-up; specific clinical populations
Formulation Development	Optimized delivery systems; rational polyherbal combinations; enhanced bioavailability
Personalized Medicine	Pharmacogenomic studies; biomarkers predicting response; responder identification
Mechanistic Studies	Systems biology approaches; genomics, proteomics, metabolomics integration
Prevention Studies	Long-term supplementation effects on age-related cognitive decline; dementia prevention trials

Table 7: Future research priorities for *Bacopa monnieri* [19]

Exploration of individual differences in response is a significant frontier. Genetic polymorphism studies of pharmacogenomics could facilitate individualized supplementation. A combination of conventional Ayurvedic ideas and modern neuroscience practices has presented promising opportunities in regard to approaches that are indeed integrative [20].

11. Conclusion

Bacopa monnieri is an outstanding example of traditional botanical medicine that has been validated by modern science. The overlap of millennia of ancient usage with the current neuropharmacological studies makes this herb a valid cognitive enhancer and neuroprotectant that requires future study. The complicated phytochemical profile of the herb has multifaceted effects on memory, cognition, and neuronal health that occur in a variety of mechanisms. Improvement of the neurotransmitter systems, stimulation of synaptic plasticity, and antioxidant, anti-inflammatory, and neuroprotective functions occur in synergistic combinations to contribute to cognitive functioning and prevention against neurodegradation.

Although this clinical evidence needs to be further developed and improved, it indicates positive outcomes on memory and cognitive processing, especially in cases where there is chronic supplementation. *B. monnieri* is also more holistic in its approach to cognitive enhancement due to its great safety profile, which puts it in a better position than synthetic cognitive enhancers.

There are still critical gaps in research, especially on long-term effectiveness, ideal dosage, mechanism of action, and treatment in certain neurological disorders. Filling in these gaps with intensive research will find out whether the promise of *B. monnieri* can be translated into clinically meaningful therapeutic effects on people with impaired cognitive abilities and neurodegenerative disease. Blending of conventional wisdom with modern neuropharmacology, as in the case of *B. monnieri* studies, is a model to be used in studying other traditional medicines. With the global burden of cognitive disorders steadily growing, there is an even stronger necessity for a safe, effective, and easily accessible intervention. *Bacopa monnieri* is a potentially vital addition to the therapeutic arsenal in the cognitive enhancement and neuroprotection of the human body due to its rich history, strong scientific evidence, and good safety profile.

References

1. Pattnaik, P., Panda, C., Minocha, T., Yadav, S. K., Dwivedi, N., & Singh, S. K. (2023). *Bacopa monnieri* and Neural Health: An Indian Herb. In *Traditional Medicine for Neuronal Health* (pp. 160-176). Bentham Science Publishers.
2. Joshi, T., Gupta, A., Kumar, P., Singh, A., & Kumar, A. (2021). *Bacopa monnieri* (brahmi). In *Naturally Occurring Chemicals Against Alzheimer's Disease* (pp. 243-256). Academic Press.
3. Anju, V., Naresh, C., & Avinash, P. (2017). Anatomical markers and Phytochemical study of different plant parts of *Bacopa monnieri* (L.) Wettst. *International Journal of Life Sciences*, 5(3), 379-386.
4. Raina, A. P., Suma, A., Holajjer, P., Sivaraj, N., & Gautam, R. K. Diversity Assessment of *Bacopa monnieri* (L.) Germplasm Using Diva-Gis Approach with Special Reference to Phytochemical Composition. *D. p. and Holajjer, P and Sivaraj, N and Gautam, RK, Diversity Assessment of Bacopa monnieri (L.) Germplasm Using Diva-Gis Approach with Special Reference to Phytochemical Composition.*
5. Kunjumon, R., Johnson, A. J., & Baby, S. (2022). *Bacopa monnieri* (Brahmi): phytochemistry and use in traditional ayurvedic formulations.
6. Lal, S., & Baraik, B. (2018). Phytochemical and pharmacological profile of *Bacopa monnieri* -An ethnomedicinal plant. *Memory*, 10(3), 1001-1013.
7. Jeyasri, R., Muthuramalingam, P., Suba, V., Ramesh, M., & Chen, J. T. (2020). *Bacopa monnieri* and their bioactive compounds inferred multi-target treatment strategy for neurological diseases: A cheminformatics and system pharmacology approach. *Biomolecules*, 10(4), 536.
8. Phrompittayarat, W., Jetiyanon, K., Wittaya-Areekul, S., Putalun, W., Tanaka, H., Khan, I., & Ingkaninan, K. (2011). Influence of seasons, different plant parts, and plant growth stages on saponin quantity and distribution in *Bacopa monnieri*. *Songklanakarin Journal of Science & Technology*, 33(2).
9. Pase, M. P., Kean, J., Sarris, J., Neale, C., Scholey, A. B., & Stough, C. (2012). The cognitive-enhancing effects of *Bacopa monnieri*: a systematic review of randomized, controlled human clinical trials. *The Journal of Alternative and Complementary Medicine*, 18(7), 647-652.
10. Aguiar, S., & Borowski, T. (2013). Neuropharmacological review of the nootropic herb *Bacopa monnieri*. *Rejuvenation research*, 16(4), 313-326.
11. Uabundit, N., Wattanathorn, J., Mucimapura, S., & Ingkaninan, K. (2010). Cognitive enhancement and neuroprotective effects of *Bacopa monnieri* in Alzheimer's disease model. *Journal of ethnopharmacology*, 127(1), 26-31.
12. Simpson, T., Pase, M., & Stough, C. (2015). *Bacopa monnieri* as an antioxidant therapy to reduce oxidative stress in the aging brain. *Evidence-Based Complementary and Alternative Medicine*, 2015(1), 615384.
13. Bhattacharya, S. K., & Ghosal, S. (1998). Anxiolytic activity of a standardized extract of *Bacopa monnieri*: an experimental study. *Phytomedicine*, 5(2), 77-82.

14. Nemetchek, M. D., Stierle, A. A., Stierle, D. B., & Lurie, D. I. (2017). The Ayurvedic plant *Bacopa monnieri* inhibits inflammatory pathways in the brain. *Journal of ethnopharmacology*, 197, 92-100.
15. Abdul Manap, A. S., Vijayabalan, S., Madhavan, P., Chia, Y. Y., Arya, A., Wong, E. H., ... & Koshy, S. (2019). *Bacopa monnieri* , a neuroprotective lead in Alzheimer disease: a review on its properties, mechanisms of action, and preclinical and clinical studies. *Drug target insights*, 13, 1177392819866412.
16. Bhardwaj, S., Rathee, V. S., & Rathee, N. K. Efficacy of *Bacopa monnieri* in Enhancing Cognitive Outcomes and Its Therapeutic Potential for ADHD: A Metasynthesis.
17. Mondal, S., Bhar, K., Mondal, P., Panigrahi, N., Sahoo, S. K., Swetha, P., ... & Parveen, N. (2023). In quest of the mysterious holistic vedic herb *Bacopa monnieri* (L.) Pennell. *Pharmacognosy Research*, 15(3).
18. Gościński, A., Stasiłowicz-Krzemień, A., Szelać, M., Pawlak, J., Skiera, I., Kwiatkowska, H., ... & Cielecka-Piontek, J. (2025). *Bacopa monnieri* : Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability. *Nutrients*, 17(11), 1939.
19. Gohil, K. J., & Patel, J. A. (2010). A review on *Bacopa monnieri*: Current research and future prospects. *International Journal of Green Pharmacy (IJGP)*, 4(1).
20. Sharma, P., Srivastava, A., & Shrivastava, N. (2025). Breeding of *Bacopa monnieri* (Brahmi): Traditional to Advanced Approaches and Future Outlook. In *Biodiversity and Genetic Improvement of Medicinal and Aromatic Plants I* (pp. 1-22). Cham: Springer Nature Switzerland.